What are the limitations of the cns ipi?

While the cns ipi is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the cns ipi to ensure safe bedside use and optimal diagnostic accuracy.

How does the cns ipi compare to other Oncology scores?

The cns ipi is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the cns ipi free to use?

Yes. OpiCalc provides the cns ipi completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

CNS-IPI

Lymphoma

Six-factor CNS relapse risk score for aggressive B-cell lymphoma.

Age > 60

ECOG >= 2

Stage III/IV

LDH elevated

>1 extranodal site

Kidney or adrenal involvement

Calculated Interpretation

Low Risk

0 Factors

Low estimated CNS relapse risk.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Six-factor CNS relapse risk score for aggressive B-cell lymphoma.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Age > 60

ECOG >= 2

Stage III/IV

LDH elevated

>1 extranodal site

Kidney or adrenal involvement

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Six-factor CNS relapse risk score for aggressive B-cell lymphoma.

OpiCalc Medical Oncology ModuleLymphoma2026

CLINICAL INSIGHT

Background

Context

CNS-IPI is included in the oncology module as a structured decision-support tool for lymphoma workflows.

No clinical reference data available.

CNS-IPI

Lymphoma

Six-factor CNS relapse risk score for aggressive B-cell lymphoma.

Age > 60

ECOG >= 2

Stage III/IV

LDH elevated

>1 extranodal site

Kidney or adrenal involvement

Calculated Interpretation

Low Risk

0 Factors

Low estimated CNS relapse risk.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Six-factor CNS relapse risk score for aggressive B-cell lymphoma.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Age > 60

ECOG >= 2

Stage III/IV

LDH elevated

>1 extranodal site

Kidney or adrenal involvement

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Six-factor CNS relapse risk score for aggressive B-cell lymphoma.

OpiCalc Medical Oncology ModuleLymphoma2026

CLINICAL INSIGHT

Background

Context

CNS-IPI is included in the oncology module as a structured decision-support tool for lymphoma workflows.

No clinical reference data available.